Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Nolu

Two GLP-1 desks, one scoreboard. We put HealthRX and Nolu head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 56 · Grade C

Nolu

Visit Nolu Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 79 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Nolu a bad call — it's best for readers who want one bundled per-order price (consult, medication, shipping) and will budget for 13 billing cycles a year rather than 12. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
76
Supply Reliability
85
82
Transparency
83
66
Access Breadth
91
90
Clinical Oversight
89
66
Track Record
81
76
HealthRXBrief Score 86 · 79Nolu

Price, coverage & the tracker

HealthRXNolu
Brief Score86/100 (B)79/100 (C)
Semaglutide$189/mo$249/mo injectable · $279/mo oral (billed per 4 weeks)
Tirzepatide$349/mo$339/mo injectable (billed per 4 weeks)
CoverageNot publicly listedAll 50 states + DC
Brand-name accessYesCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Nolu: First reading — all-in per-order pricing, but billed every 4 weeks rather than by the calendar month.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.